Loading clinical trials...

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGEARLY_PHASE1

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial

NCT01722916•Northwestern University

View on ClinicalTrials.gov

Summary

The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 18 and over
•The subjects are in good health
•The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator

Exclusion Criteria

•Under 18 years of age
•Pregnancy or Lactation
•Subjects who are unable to understand the protocol or to give informed consent
•Subjects with mental illness
•Recent Accutane use in the past 6 months
•Subjects prone to hypertrophic and keloidal scarring
•Subjects with tattoos and/or scars on upper medial arms (the treatment area)
•Subjects with known hypersensitivity to hyaluronic acid

Locations (1)

Northwestern University Department of Dermatology

Chicago, Illinois, United States

Key Dates

Start Date

October 1, 2012

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

January 31, 2025

Enrollment

ESTIMATED participants

Conditions

Drug Safety

Interventions

Hyaluronidase

DRUG

Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.

NCT06889376

Drug Safety

View study

UNKNOWNPHASE1/PHASE2

Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis

NCT04785027

Traditional Chinese MedicineDrug Effect+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase

Inclusion Criteria

Exclusion Criteria

Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.

Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

Remegal Different Doses in Patients With Refractory Partial Seizures

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.